JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio's DEX-G2 Blood Test For Early Detection of Gastric Cancer
The DESTINEX study, conducted at leading cancer centers in Japan and South Korea, evaluated a signature panel of microRNAs derived from exosomes and cell-free serum. The study analyzed 809 serum specimens from 480 participants, including patients with gastric cancer and matched controls. Using machine learning to refine and validate the assay, researchers demonstrated exceptional diagnostic accuracy for early-stage gastric cancer.
The study was led by Ajay Goel, Ph.D., AGAF, an internationally recognized leader in cancer biomarker research and the developer of the Destinex assay. Goel also serves as scientific advisor to Cizzle Bio and is chair of the Department of Diagnostics and Experimental Therapeutics at City of Hope Comprehensive Cancer Center, where he led the development of the Destinex assay into the DEX-G2 blood test that Cizzle Bio is now advancing for near-term commercial launch.
"The publication of this study in JAMA Surgery is a critical milestone, not only for our scientific team but also for the future of early gastric cancer detection," said Goel. "By combining the sensitivity of cell-free microRNAs with the specificity of exosomal markers, Destinex—and now DEX-G2—offers a minimally invasive, accessible, and highly accurate method for detecting gastric cancer at a stage when outcomes can be dramatically improved."
In the study, the Destinex assay achieved an area under the curve (AUC) of 96.8% in the validation cohort, with a sensitivity of 95.0% for detecting early-stage (pT1) gastric cancer. These findings underscore the assay's strength as a minimally invasive tool for identifying gastric cancer early when it is most curable. The assay achieved high sensitivity and specificity in distinguishing individuals with gastric cancer from those without the disease, confirming its potential not only as a minimally invasive screening tool but also to significantly improve patient outcomes through earlier detection and intervention.
A Pressing Clinical Need
Gastric cancer is the third leading cause of cancer-related deaths worldwide, mainly due to delayed diagnosis. Globally, more than 60% of gastric cancer cases are diagnosed at advanced stages, when curative treatment is no longer an option and prognosis is poor. Endoscopic screening has helped reduce mortality in high-incidence countries such as Japan and Korea, but its cost, invasiveness, and limited availability make it impractical for widespread use in low-incidence regions.
Minimally invasive blood-based tests like DEX-G2 have the potential to fill this gap. The Destinex assay, the scientific basis of DEX-G2, demonstrated outstanding sensitivity and specificity for detecting early-stage (T1) gastric cancer, and its diagnostic performance remained robust across tumor stages and patient subgroups. The study also showed a significant drop in biomarker levels after surgical tumor removal, confirming the assay's tumor specificity. Read the full JAMA Surgery study here: https://jamanetwork.com/journals/jamasurgery/fullarticle/2837074
"This study reinforces the scientific credibility and clinical utility of the technology behind DEX-G2," said Bill Behnke, CEO of Cizzle Bio. "We are proud to advance this innovation into clinical practice, where it has the potential to make earlier detection a reality for patients who currently have few options for early detection."
From Discovery to Clinical Application
Cizzle Bio is advancing its DEX-G2 test, based on the Destinex assay, for near-term commercial deployment in CLIA-certified laboratories. It is intended to support clinicians in detecting gastric cancer earlier, particularly in primary care and gastroenterology settings where endoscopy may not be accessible or practical.
The company holds a worldwide exclusive license for DEX-G2 and is actively pursuing commercialization in both U.S. and global markets, with a focus on reaching populations where gastric cancer is often diagnosed too late for curative treatment.
About Cizzle Bio
Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing biomarker-based blood tests, starting with early detection of lung and gastric cancers. Our goal is to empower patients, equip clinicians, and improve outcomes through innovation, compassion, and life-saving solutions. We hold exclusive licensing rights for our groundbreaking CIZ1B biomarker test in the United States, Canada, and the Caribbean and a worldwide exclusive license for our DEX-G2 biomarker gastric cancer test. Cizzle Bio is commercializing both tests for U.S. clinical environments.www.cizzlebio.com
Media Contact:
Yolanda Heibergeryolanda@cizzlebio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/jama-surgery-study-confirms-diagnostic-value-of-cizzle-bios-dex-g2-blood-test-for-early-detection-of-gastric-cancer-302522272.html
SOURCE Cizzle Bio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
HKUST(GZ) Launches Early Admissions with Scholarships for Two Future-Focused MSc Programs
GUANGZHOU, China, Aug. 7, 2025 /PRNewswire/ -- The Hong Kong University of Science and Technology (Guangzhou) [HKUST(GZ)] has announced early admissions for two Master of Science programs: MSc in Carbon Neutrality and Green Finance (MSc CNGF), and MSc in Technology and Policy (MSc TP). This early admission round offers several advantages, including eligibility for merit-based scholarships covering 25% to 50% of first-year tuition fees and early confirmation of study places. Applicants with outstanding academic backgrounds from top-ranked institutions, strong professional experience, or significant achievements are encouraged to apply. "These programs represent the pioneering master's programs at Society Hub, providing training that helps students master skills to deal with the significant challenges we face today," said Prof. Wu, Associate Dean of Society Hub at HKUST(GZ). "Students will benefit from our unique cross-disciplinary approach and strong industry connections within the programs." "The MSc CNGF program equips graduates to excel in sustainable finance, with coursework that includes carbon markets, ESG investing, and carbon neutrality technologies. The MSc TP program prepares students to address the governance challenges posed by emerging technologies. We have a natural advantage in being in Asia, which is increasingly viewed as the engine of technological breakthroughs," said Prof. Du, MSc Program Director of Society Hub. Both programs leverage HKUST(GZ)'s strategic location in China's most dynamic economic region, the Greater Bay Area, offering students unparalleled access to industries and innovations. The curriculum combines rigorous academic training, including internship opportunities. Established in 2022 in collaboration between HKUST and the Guangzhou Government, HKUST(GZ) is a part of HKUST's development. The two campuses operate under the "Unified HKUST, Complementary Campuses" framework, sharing faculty and research resources while maintaining identical academic standards. Its signature "Hub-Thrust" structure promotes interdisciplinary learning and nurtures globally competitive talents. As one of the four hubs at HKUST(GZ), Society Hub is dedicated to addressing global societal challenges both through technological innovation and in response to the impacts of emerging technologies in an era of unprecedented change. With a highly international and diverse faculty and student body, Society Hub welcomes applications from all backgrounds globally. Early admissions for the 2026/27 intake close on September 30, 2025. The regular application deadline for this academic year is July 15, 2026. Prospective students are encouraged to apply to secure their place and maximize scholarship opportunities. Learn more: MSc in Carbon Neutrality and Green Finance: in Technology and Policy: View original content to download multimedia: SOURCE Hong Kong University of Science and Technology (Guangzhou) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Mitsubishi Electric's ME Innovation Fund Invests in Pale Blue, Startup Developing Water-based Propulsion Systems for Satellites
TOKYO--(BUSINESS WIRE)-- Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its ME Innovation Fund has invested in Japan-based Pale Blue Inc., a startup engaged in the development, manufacturing, and sales of propulsion systems for small satellites that use water as a propellant. This is the 13th investment the fund has made to date. In recent years, the number of satellite launches has increased significantly worldwide, and the number of businesses utilizing satellite constellations has rapidly expanded. Propulsion systems, which serve as the driving force for satellite operation and orbital transfer, are critical components of satellite missions. This has led to growing demand for propulsion technologies that offer superior safety, cost efficiency, and lower environmental impact. Founded in 2020 as a deep-tech startup originating from the University of Tokyo, Pale Blue is developing proprietary water-based propulsion systems that leverage two core technologies: low-pressure, ambient-temperature water vaporization and the generation of low-power plasma with oxidation resistance, aiming to thereby realize a safe and sustainable space infrastructure. Compared to conventional propellants, water is significantly safer, more cost-effective, widely available, and environmentally friendly. Pale Blue has already completed multiple in-orbit demonstrations using small satellites, confirming the technical credibility and reliability of its solution. Pale Blue is also progressing efforts to establish its own production capabilities, which include the establishment of a production engineering development site. For the full text, please visit:
Yahoo
2 hours ago
- Yahoo
Robotic sheet that folds, grips and moves on command
It folds, moves and grips... Researchers at KAIST, a science and technology university in South Korea, have developed a paper-thin robotic sheet that can change shape in real time.
